Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups
To evaluate the utility of different risk assessments in non-muscle-invasive bladder cancer (NMIBC) patients, a total of 178 NMIBC patients from Chungbuk National University Hospital (CBNUH) were enrolled, and the predictive value of the molecular signature-based subtype predictor (MSP888) and risk...
Gespeichert in:
| Veröffentlicht in: | International journal of molecular sciences 2022-11, Vol.23 (22), p.14481 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 22 |
| container_start_page | 14481 |
| container_title | International journal of molecular sciences |
| container_volume | 23 |
| creator | Piao, Xuan-Mei Kim, Seon-Kyu Byun, Young Joon Zheng, Chuang-Ming Kang, Ho Won Kim, Won Tae Kim, Yong-June Lee, Sang-Cheol Kim, Wun-Jae Moon, Sung-Kwon Choi, Yung Hyun Yun, Seok Joong |
| description | To evaluate the utility of different risk assessments in non-muscle-invasive bladder cancer (NMIBC) patients, a total of 178 NMIBC patients from Chungbuk National University Hospital (CBNUH) were enrolled, and the predictive value of the molecular signature-based subtype predictor (MSP888) and risk calculators based on clinicopathological factors (EORTC, CUETO and 2021 EAU risk scores) was compared. Of the 178 patients, 49 were newly analyzed by the RNA-sequencing, and their MSP888 subtype was evaluated. The ability of the EORTC, MSP888 and two molecular subtyping systems of bladder cancer (Lund and UROMOL subtypes) to predict progression of 460 NMIBC patients from the UROMOL project was assessed. Cox regression analyses showed that the MSP888 was an independent predictor of NMIBC progression in the CBNUH cohort (p = 0.043). Particularly in patients without an intravesical BCG immunotherapy, MSP888 significantly linked with risk of disease recurrence and progression (both p < 0.05). However, the EORTC, CUETO and 2021 EAU risk scores showed disappointing results with respect to estimating the NMIBC prognosis. In the UROMOL cohort, the MSP888, Lund and UROMOL subtypes demonstrated a similar capacity to predict NMIBC progression (all p < 0.05). Conclusively, the MSP888 is favorable for stratifying patients to facilitate optimal treatment. |
| doi_str_mv | 10.3390/ijms232214481 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9696895</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2739440740</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-aa10a75fdeeaa62722e9e6976961e99e3c352399e689be49955943a3e92d28193</originalsourceid><addsrcrecordid>eNpdkk1v1DAQhiMEoh9w5IosceFAwF9xYg6VSrSUSi2Llt1zNE0mu14Se7Gdrfq_-IEYWqqW04w0z7zzjvRm2StG3wuh6QezHQMXnDMpK_YkO2SS85xSVT590B9kRyFsKU1goZ9nB0JJQXWhD7Nfq2gGE2-I6wmQSzdgOw3gyXezthAnj6R3nnzz2Jk2GrsmiwR4j7ZFArZLE7f2GIJxlhhLvjqbX06hHTA_t3sIZo_k0wBdh57UkJaSFkSDNoaPpHbjDrwJafXaxA2JGySz-WJZvyP1arac_z3AKWdkdroiCxN-kDPvpl14kT3rYQj48q4eZ6vPs2X9Jb-Yn53Xpxd5K1kRcwBGoSz6DhFA8ZJz1Kh0qbRiqDWKVhRcpEZV-gql1kWhpQCBmne8YlocZye3urvpasSuTbY9DM3OmxH8TePANI8n1myatds3Op2odJEE3t4JePdzwhCb0YQWhwEsuik0vJS0oEpVKqFv_kO3bvI2vZcooaWkiU1Ufku13oXgsb83w2jzJw_Nozwk_vXDD-7pfwEQvwGzzrG7</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2739440740</pqid></control><display><type>article</type><title>Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups</title><source>MEDLINE</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Piao, Xuan-Mei ; Kim, Seon-Kyu ; Byun, Young Joon ; Zheng, Chuang-Ming ; Kang, Ho Won ; Kim, Won Tae ; Kim, Yong-June ; Lee, Sang-Cheol ; Kim, Wun-Jae ; Moon, Sung-Kwon ; Choi, Yung Hyun ; Yun, Seok Joong</creator><creatorcontrib>Piao, Xuan-Mei ; Kim, Seon-Kyu ; Byun, Young Joon ; Zheng, Chuang-Ming ; Kang, Ho Won ; Kim, Won Tae ; Kim, Yong-June ; Lee, Sang-Cheol ; Kim, Wun-Jae ; Moon, Sung-Kwon ; Choi, Yung Hyun ; Yun, Seok Joong</creatorcontrib><description>To evaluate the utility of different risk assessments in non-muscle-invasive bladder cancer (NMIBC) patients, a total of 178 NMIBC patients from Chungbuk National University Hospital (CBNUH) were enrolled, and the predictive value of the molecular signature-based subtype predictor (MSP888) and risk calculators based on clinicopathological factors (EORTC, CUETO and 2021 EAU risk scores) was compared. Of the 178 patients, 49 were newly analyzed by the RNA-sequencing, and their MSP888 subtype was evaluated. The ability of the EORTC, MSP888 and two molecular subtyping systems of bladder cancer (Lund and UROMOL subtypes) to predict progression of 460 NMIBC patients from the UROMOL project was assessed. Cox regression analyses showed that the MSP888 was an independent predictor of NMIBC progression in the CBNUH cohort (p = 0.043). Particularly in patients without an intravesical BCG immunotherapy, MSP888 significantly linked with risk of disease recurrence and progression (both p < 0.05). However, the EORTC, CUETO and 2021 EAU risk scores showed disappointing results with respect to estimating the NMIBC prognosis. In the UROMOL cohort, the MSP888, Lund and UROMOL subtypes demonstrated a similar capacity to predict NMIBC progression (all p < 0.05). Conclusively, the MSP888 is favorable for stratifying patients to facilitate optimal treatment.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms232214481</identifier><identifier>PMID: 36430959</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Bladder cancer ; Cancer ; Disease Progression ; Evaluation ; Humans ; Immunotherapy ; Invasiveness ; Medical prognosis ; Muscles ; Neoplasm Invasiveness ; Neoplasm Recurrence, Local - genetics ; Neoplasm Recurrence, Local - pathology ; Patients ; Risk assessment ; Risk Factors ; Risk groups ; Tumors ; Urinary Bladder Neoplasms - genetics ; Urinary Bladder Neoplasms - pathology ; Urology</subject><ispartof>International journal of molecular sciences, 2022-11, Vol.23 (22), p.14481</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-aa10a75fdeeaa62722e9e6976961e99e3c352399e689be49955943a3e92d28193</citedby><cites>FETCH-LOGICAL-c415t-aa10a75fdeeaa62722e9e6976961e99e3c352399e689be49955943a3e92d28193</cites><orcidid>0000-0003-1925-0571 ; 0000-0001-6847-7743 ; 0000-0002-1454-3124 ; 0000-0002-4176-5187 ; 0000-0002-8060-8926 ; 0000-0001-7737-4746</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696895/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696895/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,883,27907,27908,53774,53776</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36430959$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Piao, Xuan-Mei</creatorcontrib><creatorcontrib>Kim, Seon-Kyu</creatorcontrib><creatorcontrib>Byun, Young Joon</creatorcontrib><creatorcontrib>Zheng, Chuang-Ming</creatorcontrib><creatorcontrib>Kang, Ho Won</creatorcontrib><creatorcontrib>Kim, Won Tae</creatorcontrib><creatorcontrib>Kim, Yong-June</creatorcontrib><creatorcontrib>Lee, Sang-Cheol</creatorcontrib><creatorcontrib>Kim, Wun-Jae</creatorcontrib><creatorcontrib>Moon, Sung-Kwon</creatorcontrib><creatorcontrib>Choi, Yung Hyun</creatorcontrib><creatorcontrib>Yun, Seok Joong</creatorcontrib><title>Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>To evaluate the utility of different risk assessments in non-muscle-invasive bladder cancer (NMIBC) patients, a total of 178 NMIBC patients from Chungbuk National University Hospital (CBNUH) were enrolled, and the predictive value of the molecular signature-based subtype predictor (MSP888) and risk calculators based on clinicopathological factors (EORTC, CUETO and 2021 EAU risk scores) was compared. Of the 178 patients, 49 were newly analyzed by the RNA-sequencing, and their MSP888 subtype was evaluated. The ability of the EORTC, MSP888 and two molecular subtyping systems of bladder cancer (Lund and UROMOL subtypes) to predict progression of 460 NMIBC patients from the UROMOL project was assessed. Cox regression analyses showed that the MSP888 was an independent predictor of NMIBC progression in the CBNUH cohort (p = 0.043). Particularly in patients without an intravesical BCG immunotherapy, MSP888 significantly linked with risk of disease recurrence and progression (both p < 0.05). However, the EORTC, CUETO and 2021 EAU risk scores showed disappointing results with respect to estimating the NMIBC prognosis. In the UROMOL cohort, the MSP888, Lund and UROMOL subtypes demonstrated a similar capacity to predict NMIBC progression (all p < 0.05). Conclusively, the MSP888 is favorable for stratifying patients to facilitate optimal treatment.</description><subject>Bladder cancer</subject><subject>Cancer</subject><subject>Disease Progression</subject><subject>Evaluation</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Invasiveness</subject><subject>Medical prognosis</subject><subject>Muscles</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplasm Recurrence, Local - genetics</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Patients</subject><subject>Risk assessment</subject><subject>Risk Factors</subject><subject>Risk groups</subject><subject>Tumors</subject><subject>Urinary Bladder Neoplasms - genetics</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Urology</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkk1v1DAQhiMEoh9w5IosceFAwF9xYg6VSrSUSi2Llt1zNE0mu14Se7Gdrfq_-IEYWqqW04w0z7zzjvRm2StG3wuh6QezHQMXnDMpK_YkO2SS85xSVT590B9kRyFsKU1goZ9nB0JJQXWhD7Nfq2gGE2-I6wmQSzdgOw3gyXezthAnj6R3nnzz2Jk2GrsmiwR4j7ZFArZLE7f2GIJxlhhLvjqbX06hHTA_t3sIZo_k0wBdh57UkJaSFkSDNoaPpHbjDrwJafXaxA2JGySz-WJZvyP1arac_z3AKWdkdroiCxN-kDPvpl14kT3rYQj48q4eZ6vPs2X9Jb-Yn53Xpxd5K1kRcwBGoSz6DhFA8ZJz1Kh0qbRiqDWKVhRcpEZV-gql1kWhpQCBmne8YlocZye3urvpasSuTbY9DM3OmxH8TePANI8n1myatds3Op2odJEE3t4JePdzwhCb0YQWhwEsuik0vJS0oEpVKqFv_kO3bvI2vZcooaWkiU1Ufku13oXgsb83w2jzJw_Nozwk_vXDD-7pfwEQvwGzzrG7</recordid><startdate>20221121</startdate><enddate>20221121</enddate><creator>Piao, Xuan-Mei</creator><creator>Kim, Seon-Kyu</creator><creator>Byun, Young Joon</creator><creator>Zheng, Chuang-Ming</creator><creator>Kang, Ho Won</creator><creator>Kim, Won Tae</creator><creator>Kim, Yong-June</creator><creator>Lee, Sang-Cheol</creator><creator>Kim, Wun-Jae</creator><creator>Moon, Sung-Kwon</creator><creator>Choi, Yung Hyun</creator><creator>Yun, Seok Joong</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1925-0571</orcidid><orcidid>https://orcid.org/0000-0001-6847-7743</orcidid><orcidid>https://orcid.org/0000-0002-1454-3124</orcidid><orcidid>https://orcid.org/0000-0002-4176-5187</orcidid><orcidid>https://orcid.org/0000-0002-8060-8926</orcidid><orcidid>https://orcid.org/0000-0001-7737-4746</orcidid></search><sort><creationdate>20221121</creationdate><title>Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups</title><author>Piao, Xuan-Mei ; Kim, Seon-Kyu ; Byun, Young Joon ; Zheng, Chuang-Ming ; Kang, Ho Won ; Kim, Won Tae ; Kim, Yong-June ; Lee, Sang-Cheol ; Kim, Wun-Jae ; Moon, Sung-Kwon ; Choi, Yung Hyun ; Yun, Seok Joong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-aa10a75fdeeaa62722e9e6976961e99e3c352399e689be49955943a3e92d28193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Bladder cancer</topic><topic>Cancer</topic><topic>Disease Progression</topic><topic>Evaluation</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Invasiveness</topic><topic>Medical prognosis</topic><topic>Muscles</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplasm Recurrence, Local - genetics</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Patients</topic><topic>Risk assessment</topic><topic>Risk Factors</topic><topic>Risk groups</topic><topic>Tumors</topic><topic>Urinary Bladder Neoplasms - genetics</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Piao, Xuan-Mei</creatorcontrib><creatorcontrib>Kim, Seon-Kyu</creatorcontrib><creatorcontrib>Byun, Young Joon</creatorcontrib><creatorcontrib>Zheng, Chuang-Ming</creatorcontrib><creatorcontrib>Kang, Ho Won</creatorcontrib><creatorcontrib>Kim, Won Tae</creatorcontrib><creatorcontrib>Kim, Yong-June</creatorcontrib><creatorcontrib>Lee, Sang-Cheol</creatorcontrib><creatorcontrib>Kim, Wun-Jae</creatorcontrib><creatorcontrib>Moon, Sung-Kwon</creatorcontrib><creatorcontrib>Choi, Yung Hyun</creatorcontrib><creatorcontrib>Yun, Seok Joong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Piao, Xuan-Mei</au><au>Kim, Seon-Kyu</au><au>Byun, Young Joon</au><au>Zheng, Chuang-Ming</au><au>Kang, Ho Won</au><au>Kim, Won Tae</au><au>Kim, Yong-June</au><au>Lee, Sang-Cheol</au><au>Kim, Wun-Jae</au><au>Moon, Sung-Kwon</au><au>Choi, Yung Hyun</au><au>Yun, Seok Joong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2022-11-21</date><risdate>2022</risdate><volume>23</volume><issue>22</issue><spage>14481</spage><pages>14481-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>To evaluate the utility of different risk assessments in non-muscle-invasive bladder cancer (NMIBC) patients, a total of 178 NMIBC patients from Chungbuk National University Hospital (CBNUH) were enrolled, and the predictive value of the molecular signature-based subtype predictor (MSP888) and risk calculators based on clinicopathological factors (EORTC, CUETO and 2021 EAU risk scores) was compared. Of the 178 patients, 49 were newly analyzed by the RNA-sequencing, and their MSP888 subtype was evaluated. The ability of the EORTC, MSP888 and two molecular subtyping systems of bladder cancer (Lund and UROMOL subtypes) to predict progression of 460 NMIBC patients from the UROMOL project was assessed. Cox regression analyses showed that the MSP888 was an independent predictor of NMIBC progression in the CBNUH cohort (p = 0.043). Particularly in patients without an intravesical BCG immunotherapy, MSP888 significantly linked with risk of disease recurrence and progression (both p < 0.05). However, the EORTC, CUETO and 2021 EAU risk scores showed disappointing results with respect to estimating the NMIBC prognosis. In the UROMOL cohort, the MSP888, Lund and UROMOL subtypes demonstrated a similar capacity to predict NMIBC progression (all p < 0.05). Conclusively, the MSP888 is favorable for stratifying patients to facilitate optimal treatment.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>36430959</pmid><doi>10.3390/ijms232214481</doi><orcidid>https://orcid.org/0000-0003-1925-0571</orcidid><orcidid>https://orcid.org/0000-0001-6847-7743</orcidid><orcidid>https://orcid.org/0000-0002-1454-3124</orcidid><orcidid>https://orcid.org/0000-0002-4176-5187</orcidid><orcidid>https://orcid.org/0000-0002-8060-8926</orcidid><orcidid>https://orcid.org/0000-0001-7737-4746</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1422-0067 |
| ispartof | International journal of molecular sciences, 2022-11, Vol.23 (22), p.14481 |
| issn | 1422-0067 1661-6596 1422-0067 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9696895 |
| source | MEDLINE; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Bladder cancer Cancer Disease Progression Evaluation Humans Immunotherapy Invasiveness Medical prognosis Muscles Neoplasm Invasiveness Neoplasm Recurrence, Local - genetics Neoplasm Recurrence, Local - pathology Patients Risk assessment Risk Factors Risk groups Tumors Urinary Bladder Neoplasms - genetics Urinary Bladder Neoplasms - pathology Urology |
| title | Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T08%3A32%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Utility%20of%20a%20Molecular%20Signature%20for%20Predicting%20Recurrence%20and%20Progression%20in%20Non-Muscle-Invasive%20Bladder%20Cancer%20Patients:%20Comparison%20with%20the%20EORTC,%20CUETO%20and%202021%20EAU%20Risk%20Groups&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Piao,%20Xuan-Mei&rft.date=2022-11-21&rft.volume=23&rft.issue=22&rft.spage=14481&rft.pages=14481-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms232214481&rft_dat=%3Cproquest_pubme%3E2739440740%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2739440740&rft_id=info:pmid/36430959&rfr_iscdi=true |